fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Nippon India PHARMA Fund

Nippon India PHARMA Fund - G

NAV  ₹465.463 ↓ -0.09  (-0.02 %) as on 16 Jul 24

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 21% since its launch.  Ranked 35 in Sectoral category.  Return for 2023 was 39.2% , 2022 was -9.9% and 2021 was 23.9% .

Below is the key information for Nippon India Pharma Fund

NAV as on 16 Jul 24₹465.463 ↓ -0.09  (-0.02 %)
Net Assets (AUM) as on 31 May 2024 ₹7,161 Cr.
Launch Date5 Jun 2004
CategoryEquity - Sectoral
Rating
TypeOpen Ended Fund
RiskHigh
AMCNippon Life Asset Management Ltd.
Alpha Ratio3.6
Expense Ratio1.97 %
Sharpe Ratio2.325
Information Ratio0.27
BenchmarkNot Available
Min Investment ₹5,000
Min SIP Investment ₹100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 16 Jul 24

DurationReturns
1 Month 2.9%
3 Month 9.8%
6 Month 14.8%
1 Year 43.6%
3 Year 14.1%
5 Year 26.5%
10 Year
15 Year
Since launch 21%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

YearReturns
2023 39.2%
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%

Growth of 10k Over Years

DateValue
30 Jun 19₹10,000
30 Jun 20₹13,299
30 Jun 21₹21,524
30 Jun 22₹18,381
30 Jun 23₹22,333
30 Jun 24₹31,441
Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset ClassValue
Cash1.62%
Equity98.38%
Nippon India PHARMA Fund Asset Allocation

Sector Allocation

SectorValue
Health Care98.38%
Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

NameGlobal IndustryHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
Drug Manufacturers - Specialty & Generic13%₹957 Cr6,556,349
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
Drug Manufacturers - Specialty & Generic8%₹554 Cr3,503,676
↓ -200,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
Drug Manufacturers - Specialty & Generic8%₹539 Cr1,250,808
↑ 350,000
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
Drug Manufacturers - General6%₹449 Cr3,100,000
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
Medical Care Facilities5%₹379 Cr648,795
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
Drug Manufacturers - Specialty & Generic4%₹319 Cr550,030
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
Drug Manufacturers - General4%₹313 Cr1,700,000
Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Jan 18 | 532321
Drug Manufacturers - Specialty & Generic4%₹270 Cr2,700,632
Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 543350
Diagnostics & Research4%₹257 Cr3,161,151
J.B. Chemicals & Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Jan 22 | JBCHEPHARM
Drug Manufacturers - Specialty & Generic3%₹227 Cr1,278,814
↓ -108,054
1 - 10 of 35
Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Managers

NameSinceTenure
Sailesh Raj Bhan1 Apr 0519.18 Yr.
Kinjal Desai25 May 186.02 Yr.

Custodians

CompanyAddress
Deutsche Bank AGDeutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
AddressKFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar,
FAX91-40-23311968
Emailmailmanager@karvy.com

Administrator Companies

CompanyAddress
Nippon India Mutual Fund9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

CompanyAddress
Haribhakti & Co. Chartered Accountants42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and PlanNAV6 Month1 Year3 Year5 Year
Nippon India Pharma Fund
Normal Dividend, Payout
₹118.508
↓ -0.02
13.95 %42.53 %15.45 %29.07 %
Nippon India Pharma Fund
Normal Dividend, Reinvestment
₹118.508
↓ -0.02
13.95 %42.53 %15.45 %29.07 %
Nippon India Pharma Fund
Growth
₹465.463
↓ -0.09
14.79 %43.59 %14.11 %26.48 %
Data as on 16 Jul 24

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.